Literature DB >> 15552405

Meta-analysis of age-prevalence patterns in lymphatic filariasis: no decline in microfilaraemia prevalence in older age groups as predicted by models with acquired immunity.

W A Stolk1, K D Ramaiah, G J Van Oortmarssen, P K Das, J D F Habbema, S J De Vlas.   

Abstract

The role of acquired immunity in lymphatic filariasis is uncertain. Assuming that immunity against new infections develops gradually with accumulated experience of infection, models predict a decline in prevalence after teenage or early adulthood. A strong indication for acquired immunity was found in longitudinal data from Pondicherry, India, where Mf prevalence was highest around the age of 20 and declined thereafter. We reviewed published studies from India and Subsaharan Africa to investigate whether their age-prevalence patterns support the models with acquired immunity. By comparing prevalence levels in 2 adult age groups we tested whether prevalence declined at older age. For India, comparison of age groups 20-39 and 40+ revealed a significant decline in only 6 out of 53 sites, whereas a significant increase occurred more often (10 sites). Comparison of older age groups provided no indication that a decline would start at a later age. Results from Africa were even more striking, with many more significant increases than declines, irrespective of the age groups compared. The occurrence of a decline was not related to the overall Mf prevalence and seems to be a chance finding. We conclude that there is no evidence of a general age-prevalence pattern that would correspond to the acquired immunity models. The Pondicherry study is an exceptional situation that may have guided us in the wrong direction.

Entities:  

Mesh:

Year:  2004        PMID: 15552405     DOI: 10.1017/s0031182004005980

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  7 in total

1.  High prevalence of Wuchereria bancrofti infection as detected by immunochromatographic card testing in five districts of Orissa, India, previously considered to be non-endemic.

Authors:  Patricia K Foo; Alessandro Tarozzi; Aprajit Mahajan; Joanne Yoong; Lakshmi Krishnan; Daniel Kopf; Brian G Blackburn
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-11-30       Impact factor: 2.184

2.  A cohort study of lymphatic filariasis on socio economic conditions in Andhra Pradesh, India.

Authors:  Suryanaryana Murty Upadhyayula; Srinivasa Rao Mutheneni; Madhusudhan Rao Kadiri; Sriram Kumaraswamy; Balakrishna Nagalla
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

3.  Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling.

Authors:  Wilma A Stolk; Sake J de Vlas; J Dik F Habbema
Journal:  Filaria J       Date:  2006-03-28

4.  A case study of risk factors for lymphatic filariasis in the Republic of Congo.

Authors:  Cédric B Chesnais; François Missamou; Sébastien D Pion; Jean Bopda; Frédéric Louya; Andrew C Majewski; Peter U Fischer; Gary J Weil; Michel Boussinesq
Journal:  Parasit Vectors       Date:  2014-07-01       Impact factor: 3.876

5.  Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.

Authors:  Wilma A Stolk; Quirine A ten Bosch; Sake J de Vlas; Peter U Fischer; Gary J Weil; Ann S Goldman
Journal:  PLoS Negl Trop Dis       Date:  2013-01-03

6.  Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects.

Authors:  Subramanian Swaminathan; Pani P Subash; Ravi Rengachari; Krishnamoorthy Kaliannagounder; Das K Pradeep
Journal:  Parasit Vectors       Date:  2008-02-12       Impact factor: 3.876

7.  Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.

Authors:  Purushothaman Jambulingam; Swaminathan Subramanian; S J de Vlas; Chellasamy Vinubala; W A Stolk
Journal:  Parasit Vectors       Date:  2016-09-13       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.